37 completed, 11 terminated, 5 recruiting, 5 withdrawn. 66 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 66 | Completed 37, Terminated 11, Recruiting 5, Withdrawn 5, Active not recruiting 4, Unknown 3, Not yet recruiting 1 |
| Phase 1 | 7 | Completed 3, Active not recruiting 2, Terminated 2 |
Follow Pemetrexed Disodium: new trials by email Literature Review of Pemetrexed Disodium trials Research Report on Pemetrexed Disodium
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer ArmA:GFH375, Arm B:GFH375, Arm C:GFH375 - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | 90 | 2026-05-20 | 2026-04-28 |
| A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] LBL-024 for Injection, Docetaxel Injection, Bevacizumab Injection - Advanced Solid Tumour | Phase 2 | Recruiting | Nanjing Leads Biolabs Co.,Ltd | 250 | 2025-06-11 | 2026-08-27 |
| Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer Tislelizumab, Cisplatin, Carboplatin - Lung Cancer, Non-Small Cell | Phase 2 | Recruiting | Shanghai Chest Hospital | 32 | 2024-11-20 | 2025-05-18 |
| A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors BL-B01D1, PD-1 Monoclonal Antibody, Pemetrexed Disodium - Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma | Phase 2 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 570 | 2024-06-25 | 2026-07-23 |
| Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma Atezolizumab, Bevacizumab, Biospecimen Collection - Peritoneal Malignant Mesothelioma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 66 | 2022-03-22 | 2026-10-26 |
| MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer Pembrolizumab, Pemetrexed Disodium, Biospecimen Collection - Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma | Phase 2 | Active not recruiting | Mayo Clinic | 45 | 2021-07-23 | 2026-06-04 |
| Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC Biological: Camrelizumab, Pemetrexed, Nab-paclitaxel - Early Stage Non-small Cell Lung Cancer | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 30 | 2020-09-25 | 2020-11-13 |
| Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Cisplatin, Pembrolizumab, Pemetrexed - Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8 | Phase 2 | Withdrawn | University of California, San Francisco | 2020-05-29 | 2022-03-04 | |
| Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) Docetaxel, Gemcitabine, Gemcitabine Hydrochloride - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Completed | SWOG Cancer Research Network | 166 | 2019-05-28 | 2024-09-03 |
| Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC IBI308, Bevacizumab, Pemetrexed - Lung Cancer Stage III | Phase 2 | Recruiting | Sun Yat-sen University | 36 | 2019-03-01 | 2026-04-21 |
| Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC. JS001, Pemetrexed, Carboplatin - Efficacy and Safety | Phase 2 | Withdrawn | Sun Yat-sen University | 2019-02-01 | 2024-12-06 | |
| Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer Nivolumab, Cisplatin, Pemetrexed Disodium - Non-Squamous Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 14 | 2017-12-20 | 2026-02-20 |
| Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer Laboratory Biomarker Analysis, Pemetrexed Disodium - Metastatic Urothelial Carcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 7 | 2017-05-09 | 2021-05-20 |
| Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer 3-Dimensional Conformal Radiation Therapy (3D-CRT), Docetaxel, Gemcitabine - Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | NRG Oncology | 218 | 2017-04-07 | 2026-06-08 |
| Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin Cisplatin, Methoxyamine, Pemetrexed Disodium - Advanced Malignant Solid Neoplasm, Advanced Peritoneal Malignant Mesothelioma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 30 | 2016-03-08 | 2026-07-31 |
| Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery Cisplatin, Computed Tomography, Docetaxel - Stage IIIA Non-Small Cell Lung Cancer | Phase 2 | Withdrawn | ECOG-ACRIN Cancer Research Group | 2015-11-19 | 2023-05-25 | |
| Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3 Laboratory Biomarker Analysis, Pemetrexed Disodium, Quality-of-Life Assessment - Stage IV Non-Small Cell Lung Cancer | Phase 2 | Completed | Wake Forest University Health Sciences | 16 | 2015-05-01 | 2023-10-12 |
| High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases pemetrexed - Brain Metastases | Phase 2 | Unknown | Rongjie Tao | 25 | 2014-11-01 | 2014-11-06 |
| S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib crizotinib, pemetrexed disodium, laboratory biomarker analysis - Adenocarcinoma of the Lung, Large Cell Lung Cancer | Phase 2 | Terminated | SWOG Cancer Research Network | 1 | 2014-08-01 | 2020-02-20 |
| Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib pemetrexed disodium, carboplatin, cisplatin - Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | Phase 2 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2014-06-01 | 2015-07-13 |
Showing 20 of 66. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (36) · Lung Neoplasms (23) · Adenocarcinoma of Lung (8) · Mesothelioma, Malignant (7) · Adenocarcinoma, Bronchiolo-Alveolar (5) · Solitary Fibrous Tumor, Pleural (4) · Brain Neoplasms (3) · Breast Neoplasms (2) · Head and Neck Neoplasms (2) · Neoplasm Metastasis (2) · Ovarian Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Uterine Cervical Neoplasms (2) · Astrocytoma (1) · Bile Duct Neoplasms (1)
Alliance for Clinical Trials in Oncology (9) · National Cancer Institute (NCI) (7) · Gynecologic Oncology Group (5) · SWOG Cancer Research Network (3) · Sun Yat-sen University (3) · University of California, Davis (3) · Vanderbilt-Ingram Cancer Center (3) · Albert Einstein College of Medicine (2) · Barbara Ann Karmanos Cancer Institute (2) · Eastern Cooperative Oncology Group (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · Mayo Clinic (2) · Northwestern University (2) · UNC Lineberger Comprehensive Cancer Center (2) · Wake Forest University Health Sciences (2)
United States (51) · China (9) · Belgium (2) · Canada (2) · United Kingdom (2) · France (1) · Israel (1) · Italy (1) · Netherlands (1) · Saudi Arabia (1) · Sweden (1)
David S. Miller, MD (5) · Alex A. Adjei, MD, PhD (4) · Grace K. Dy, MD (2) · Leora Horn (2) · Thomas E. Stinchcombe, MD (2) · Aaron S Mansfield (1) · Afshin Dowlati, MD (1) · Allan Covens, MD (1) · Amelie Lansiaux, MD, PhD (1) · Angela Davies, MD (1) · Anne S Tsao (1) · Antoinette J. Wozniak, MD (1) · Arkadiusz Dudek, MD (1) · Ashish Chintakuntlawar, MBBS, PhD (1)
PMID 16135464, PMID 16303865, PMID 18090584, PMID 18455781, PMID 18459175, PMID 19023677, PMID 19494788, PMID 19804902, PMID 19841321, PMID 20209614, PMID 20525721, PMID 20651609, PMID 21415776, PMID 21684151, PMID 21747084, PMID 22362813, PMID 22584333, PMID 23420398, PMID 24013936, PMID 24090033, PMID 24099865, PMID 24133369, PMID 24985049, PMID 25057165, PMID 25081901, PMID 26774201, PMID 30642285, PMID 31386610, PMID 33608212, PMID 35379845, PMID 37673112
P30CA022453 (3), U10CA031946 (3), U10CA032102 (3), U10CA180821 (3), U10CA180888 (3), P30CA012197 (2), P30CA013330 (2), P30CA068485 (2), U10CA021115 (2), 2004 (1), 2005 (1), P30CA006973 (1), P30CA015083 (1), P30CA015704 (1), P30CA016086 (1)